The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma
Georgina V. Long
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - GlaxoSmithKline; Roche
Daniil L. Stroyakovsky
No relevant relationships to disclose
Helen Gogas
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche
Honoraria - Bristol-Myers Squibb
Eugeny Levchenko
No relevant relationships to disclose
Filippo de Braud
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche
James M. G. Larkin
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer
Claus Garbe
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Thomas Jouary
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; IMS Health; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Axel Hauschild
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Other Remuneration - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Jean Jacques Grob
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Vanna Chiarion-Sileni
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Celeste Lebbe
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Mario Mandalà
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Michael Millward
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Douglas James DeMarini
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Jhangir G Irani
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ngocdiep Le
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michelle Casey
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kiran Patel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Keith Flaherty
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline